40 results about "Hemoglobin F" patented technology

A method of determining glycated hemoglobin is provided, by which a ratio of the glycated hemoglobin in a sample can be determined accurately and easily. The ratio of glycated hemoglobin can be determined by degrading a glycated hemoglobin in a whole blood sample selectively with a protease to give a glycated hemoglobin degradation product`; causing a redox reaction between a glycation site of the glycated hemoglobin degradation product and a fructosyl amino acid oxidoreductase; and determining this redox reaction. Further, as shown in FIG. 1, in a whole blood sample, there is a correlation between the ratio of the glycated hemoglobin determined by this method and an HbA1c concentration. Thus, without determining the glycated alpha-amino group as a characteristic structure of HbA1c, an amount of HbA1c can be determined accurately and easily from the determined ratio of the glycated hemoglobin.

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

A method for measuring the absolute concentration of oxygenated and reduced hemoglobin in human tissue features that its sensor is composed of 2 photoelectric receiving tubes and at least 3 light sources with different wavelengths, which are arranged on a straight line at intervals. Said absolute concentration can be calculated out. Said light source can emit respectively red light and near infrared light.

Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.

Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein.

The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-microglobulin as markers for preeclampsia.

A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to the organs and the peripheral tissues in human bodies. The compound of phthalides is characterized by a phthalide functional group, and forms at least one hydrogen bond with [alpha]Arg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes, stabilizing the [alpha]1 / [alpha]2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity 'T' state and facilitating the oxygen release to the organs and the peripheral tissues. A medication for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin, and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is also disclosed.

The present invention provides methods of detecting cancer using biomarkers.

The present invention discloses a method for measuring glycosylated hemoglobin by isotope dilution liquid chromatography-tandem mass spectrometry. The method comprises the following steps: 1) a mole <15>N-HbA1c-<13>C and b mole <15>N-HbA0-<13>C both are added into a standard substance solution and a to-be-tested sample, the standard substance solution and the to-be-tested sample pass by a solid phase extraction column to obtain a to-be-loaded standard substance and a to-be-loaded to-be-tested sample, <15>N-HbA1c-<13>C is a hexapeptide chain at the N terminal of an isotope 15N and 13C-labeled glycosylated hemoglobin beta chain, the <15>N-HbA0-<13>C is a hexapeptide chain at the N terminal of an isotope 15N and 13C-labeled non-glycosylated hemoglobin beta chain, and a and b both are greater than 0; 2) the to-be-loaded standard substance and the to-be-loaded to-be-tested sample are respectively detected by a liquid chromatography-tandem mass spectrometer; and 3) the content of the glycated hemoglobin in the to-be-tested sample can be obtained from the testing results of the step 2). The method is simple in operation, is more accurate and precise than a mass spectrometric method recommended by IFCC, has good specificity and sensitivity, and is expected to become a decisive reference method for the determination of the glycated hemoglobin.

An hemoglobin (Hb)-Dextran (Dx) conjugate having a molecular weight between 50 kd and 500 kD provides a blood substitute that results in acceptable erythrocyte sedimentation rate (ESR) and excretion rate (EXC) values. DxHb conjugates of the invention can be used for a variety of purposes as an alternative to blood.

The present invention relates to the immunology and sugar technology, aiming to take advantage of the immunology principles to measure the glucan content in the sugar and to propose a preparation method for glucan monoclonal antibody. The present invention comprises the following steps: A. The selection and coupling of antigen. Shikongqi hemoglobin and bovine serum albumin are respectively coupled with glucan to generate antigen; B. Animal immunity and blood test; C. cell fusion and cultivation; D. Hybridoma screening; E. Hybridoma cloning; F. preparation of hybridoma ascites. The present invention is of substantive features and notable progress: 1. rich raw materials, 2. safe and reliability 3. Glucan-specific monoclonal antibody can be gained and can be substantially cultivated; glucan-specific monoclonal antibody can be easily used to achieve sandwich ELISA immunology kit that can quantitatively measure the glucan. The present invention makes the fast and accurate measurement of glucan in sugar cane source, manufactured products possible.

Non-naturally occurring mutant hemoglobins rHb (.beta.N108Q) and rHb (.beta.L105W) are provided that have a lower oxygen affinity than that of native hemoglobin, but high cooperativity in oxygen binding. rHb (.beta.N108Q) also exhibits enhanced stability against autoxidation. The mutant hemoglobins are preferably produced by recombinant DNA techniques. Such mutant hemoglobins may be used as a component of a blood substitute and hemoglobin therapeutics.

The present invention relates to haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof or a mimic thereof being operably linked to a substance and capable of binding a CD163 receptor. Furthermore, the invention relates to a CD163 variant, membrane bound or soluble, capable of binding at least one haptoglobin-haemoglobin (Hp-Hb) complex, and the use of the Hp-Hb complex and the CD163 receptor for therapy.

A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-micro-globulin as markers for preeclampsia.

The present invention is a method for preparing a hemoglobin based oxygen carrier to deliver oxygen to tissue. The method comprises mixing a deoxygenated hemoglobin with a maleimide-activated polyakylene oxide (PAO) to obtain an oxygen carrying product. This product is characterized as having 2 to about 8 PAO moieties covalently bound to a deoxygenated hemoglobin and a p50 less than native stroma-free hemoglobin from the same animal source when measured under the same conditions.

The invention relates to an anti-porcine hemoglobin hybridoma cell strain, and a monoclonal antibody and an application of the anti-porcine hemoglobin hybridoma cell strain, and belongs to the technical field of immunology. The anti-porcine hemoglobin hybridoma cell strain PHb-3B4 has a collection number of CCTCC NO (China Center for Type Culture Collection number): C201784. The anti-porcine hemoglobin monoclonal antibody is generated by the anti-porcine hemoglobin hybridoma cell strain; a subtype is IgG1 (immune globulin G1); the valence is 1:819200; an affinity constant is 2.8*10<8>L / mol; and cross reaction rates of the monoclonal antibody with bovine hemoglobin and human hemoglobin are less than 0.1%. The anti-porcine hemoglobin monoclonal antibody is used for detecting porcine hemoglobin, and has the advantages of high valence, good sensitivity and high specificity. The porcine hemoglobin monoclonal antibody can be used for developing an immunological diagnostic reagent related tothe porcine hemoglobin, such as a colloidal gold test strip, a fluorescence detection test strip and an ELISA (enzyme-linked immuno sorbent assay) reagent kit.

The invention relates to active polypeptides from a human placenta, which are derived from hemoglobin. The invention also relates to a composition comprising the polypeptides and application of the composition. A small-molecule substance with a molecular weight below 10KD in the human placenta is extracted from the human placenta by using a positive hepatitis B virus (HBV) surface antibody (HBsAb) to prepare injections including a liquid injection and a powder injection. According to the invention, the polypeptides in an extract are preliminarily analyzed by using a method of proteomics to obtain 5 types of human placental immunocompetent polypeptides derived from hemoglobin, and experimental studies show that the human placental immunocompetent polypeptides have immunological competence.

The invention relates to a pluri-negative-charge hemoglobin alpha subunit, and relates to a component of a hemoglobin red blood cell substitute artificial blood. The invention relates to the technical field of biomedicine. The pluri-negative-charge hemoglobin alpha subunit is a fusion protein composed of human serum albumin and human hemoglobin alpha subunit. The human serum albumin and human hemoglobin are connected through connecting peptide. The preparation method comprises the following steps: with a PCR amplification method or a chemical total synthesis method, a fusion protein polypeptide chain amino acid sequence is synthesized; the fusion protein polypeptide chain amino acid sequence is cloned to a prokaryotic expression vector; the expression vector is transformed into cells of an expression system; with an induction method, effective cells are identified; and the cells are subjected to separation and purification. The fusion protein has large molecular weight and carries a lot of negative charges. With the two factors, even a fusion protein in the form of a monomer cannot pass kidney filtration, such that side effect to ahuman body is reduced. The human serum albumin can be bonded with heme. Therefore, when the fusion protein is used for preparing artificial blood, higher bonding capability and higher oxygen transportation capacity are provided.

The present invention provides novel recombinant nucleic acid vectors which may be used to produce alpha -globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The present invention also provides for the transgenic animals which contain these recombinant nucleic acid vectors. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the beta -globin locus together with a gene of interest. According to various embodiments of the invention, the vectors may be used to create transgenic animals or to transfect cells in culture. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human alpha -globin gene is used to create transgenic animals which produce human alpha -globin protein in erythroid tissues, including red blood cells. In a preferred specific embodiment of the invention, transgenic animals are created which comprise human alpha -globin and beta -globin genes, each under the transcriptional influence of two beta -globin locus DNase hypersensitivity sites; these transgenic animals express human hemoglobin in their erythroid tissues, and can be used to produce human hemoglobin in quantity.

Devices, kits, and assays are provided for the testing and monitoring of hemoglobin, anemia, glucose-6-phoshate dehydrogenase, and glucose-6-phosphate dehydrogenase deficiency in an individual.

The present invention relates to a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum. A method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody (βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 100 kDa. The method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of diseases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomelic and degraded hep-toglobins can be specifically measured by the said method.

The present invention provides methods of detecting cancer using biomarkers.

The present invention relates to the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human animals and erythroid cell lines. It is based on the discovery that two of the five hypersensitivity sites of the beta-globin locus are sufficient to result in high level expression of human alpha- or beta-globin transgenes.